Latest Commercialisation News

EBR Systems has signed a long-term lease for a 51,000 sq ft facility in Santa Clara, California, positioning itself for significant manufacturing expansion and future growth in wireless cardiac pacing technology.

Dimerix Limited has inked a lucrative licensing agreement with Fuso Pharmaceutical for its kidney disease drug DMX-200 in Japan, while completing recruitment for its pivotal Phase 3 ACTION3 trial.

First Graphene has secured key patents for its Kainos Technology in Australia and Korea, positioning itself at the forefront of producing graphite, graphene, and hydrogen from petroleum waste. This milestone aligns with growing global demand for critical minerals essential to the energy transition.

Telix Pharmaceuticals has finalized its acquisition of RLS (USA) Inc., significantly expanding its radiopharmaceutical footprint across the United States with a network of over 30 radiopharmacies.

Entyr Limited has launched a $9.5 million capital raising via a Share Purchase Plan and Placement Offer, aiming to recapitalize and return to ASX trading following its recent voluntary administration.

Invictus Energy has completed a key legal review and secured $12 million in funding, setting the stage for expanded drilling and development in Zimbabwe's Cabora Bassa Basin.

TMK Energy has successfully doubled its pilot production capacity at the Gurvantes XXXV Coal Seam Gas project and inked an early commercialisation deal to supply gas for power generation, positioning itself as a pioneer in Mongolia's emerging CSG sector.

Respiri Limited reports a standout December quarter marked by a 67% surge in patient program enrolments and robust revenue growth, bolstered by strategic acquisition synergies from Orb Health. The company is poised for further expansion in 2025 amid promising contract negotiations and evolving US healthcare reimbursement policies.

Adisyn Ltd has successfully raised $10 million through a heavily oversubscribed placement, signaling strong institutional confidence in its graphene-enhanced semiconductor technology. The capital will accelerate development, commercial partnerships, and operational scaling.

Biotron Limited has engaged US-based C14 Consulting Group to drive strategic partnerships for its antiviral drug portfolio, including lead candidate BIT225, while advancing its Hepatitis B research.

Conrad Asia Energy reports solid progress in Q4 2024 with finalized gas sales agreements and promising LNG studies, despite delayed final investment decisions due to regulatory approvals.

Sparc Technologies has committed to Stage 2 of its hydrogen joint venture, secured a pioneering patent in Morocco, and progressed graphene additive trials, signaling momentum in its clean energy and materials innovation.